BERGEN, Norway, May 13, 2020 /PRNewswire/ -- BerGenBio ASA
(OSE: BGBIO), will announce its results for the first quarter 2020
on Tuesday 19 May 2020. A webcast
presentation by BerGenBio's senior management team will take place
at 10 am CET.
The presentation will webcast live and the link will be
available at www.bergenbio.com in the section
Investors/Financial Reports. A recording will be available shortly
after the webcast has finished.
The results report and presentation will be available
at www.bergenbio.com in the section: Investors/Financial
Reports from 7:00 am CET the same
day.
About BerGenBio
BerGenBio is a clinical-stage biopharmaceutical company focused
on developing transformative drugs targeting AXL as a potential
cornerstone of therapy for aggressive diseases, including
immune-evasive, therapy resistant cancers. The company's
proprietary lead candidate, bemcentinib, is a potentially
first-in-class selective AXL inhibitor in a broad Phase II oncology
clinical development programme focused on combination and single
agent therapy in lung cancer and leukaemia. A first-in-class
functional blocking anti-AXL antibody, tilvestamab, is undergoing
Phase I clinical testing. In parallel, BerGenBio is developing a
companion diagnostic test to identify those patient populations
most likely to benefit from bemcentinib: this is expected to
facilitate more efficient registration trials supporting a
precision medicine-based commercialisation strategy. BerGenBio is
based in Bergen, Norway with a
subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO).
For more information, please contact:
Richard Godfrey
CEO, BerGenBio ASA
+47-917-86-304
Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47-917-86-513
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy
Featherstone, Carina
Jurs,
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44-20-3709-5700
Media Relations in Norway
Jan Petter Stiff, Crux
Advisers
stiff@crux.no
+47-995-13-891
For more information, visit www.bergenbio.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bergenbio-asa/r/bergenbio-asa--invitation-to-first-quarter-2020-results-webcast-presentation,c3110120
View original
content:http://www.prnewswire.com/news-releases/bergenbio-asa-invitation-to-first-quarter-2020-results-webcast-presentation-301058298.html
SOURCE BerGenBio ASA